Regulatory Pathways: When to Submit a 505(b)(2) or an ANDA
Successfully advancing new drugs and life-saving therapies to market for emerging pharma and biotech organizations, involves complex challenges throughout product development. For these companies, choosing the right regulatory pathway can significantly impact the success of bringing innovative therapies to market.
This webinar discusses best practices and key strategies to consider when choosing the best regulatory pathway for new drug application submissions as well as recommends strategies for early-stage biopharma companies to achieve successful outcomes.
Join us on Thursday, August 4 at 1:00 pm ET for critical insights and key considerations for selecting the best regulatory pathway to ensure success for new drug applications (NDA) submissions. Explore the latest strategies for advancing ANDA and 505(b)(2) submissions with Sharon Ayd, Ph.D., Vice President & Principal Regulatory Center of Excellence (CoE) Advarra Consulting.
Learning Objectives:
-
Gain an in-depth understanding of the ANDA and 505(b)(2) process
-
Learn successful strategies for advancing your NDA submission
-
Understand how to identify and mitigate regulatory risk factors in your go-to-market strategy
-
Understand the importance of developing a regulatory strategy
Presented By
Sharon Ayd
Ph.D, MBA
Vice President & Principal
Advarra Consulting
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
DATE: June 17, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour